PRESENTATION

Q2 2022 — Results presentation

Q2 2022PDF · 27 pages3.9 MB
1

-- 1 of 27 --

Cautionary Note on Forward-looking Statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on
these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as
interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product
research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally
or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability
claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government
agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to
successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone
publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures
implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the company’s ability to execute business
continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form
10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson &
Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or
on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update
any forward-looking statement as a result of new information or future events or developments.
Cautionary Note on Non-GAAP Financial Measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm.
2

-- 2 of 27 --

Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.
Infectious Diseases
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in
part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development
Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
at the U.S. Department of Health and Human Services (HHS)
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; cilta-cel licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S
relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Strategic Partnerships,
Collaborations & Licensing Arrangements
3
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:

-- 3 of 27 --

Joaquin Duato
Chief Executive Officer
2nd Quarter 2022
Earnings Call
July 19, 2022

-- 4 of 27 --



-- 5 of 27 --



-- 6 of 27 --



-- 7 of 27 --



-- 8 of 27 --

Note: Roles to be assumed upon completion of the planned separation, expected to occur in 2023
New Consumer Health Company
Designate Leadership Team
Luani Alvarado
Chief People Officer
People Experience, Diversity, Equity
& Inclusion, Talent Development,
Compensation, Health & Well-Being,
and HR Business Partners and
Operations
Rosana Padilla
President, Latin America
Donna Lorenson
Chief Corporate Affairs
Officer
Corporate Communications, Public
Affairs, Government Affairs & Policy,
and Global Community Impact
Ellesha Kirby
Global Head, Skin Health
& Beauty and Design
Meri Stevens
Chief Operations Officer
End-to-end Quality, Supply Chain
and Procurement
Ellie Bing Xie
Group President,
Asia Pacific
Caroline Tillett
Chief Scientific Officer
Research & Development, Medical
Affairs, Medical Safety, and
Regulatory Affairs
Carlton Lawson
Group President,
Europe, Middle East and
Africa
Katie Decker
Global Head, Essential
Health and Customer
Engagement
Manoj
Raghunandanan
Global Head, Self Care
and Consumer Experience
Organization (CxO)
Jan Meurer
Chief Growth Officer
Global Franchise Organizations,
Global Strategy, Business
Development & Ventures, ESG
Office, and the Office of the CEO
Kathy Widmer
Group President,
North America and Latin
America
Natasha Zuyev
Chief Quality Officer
Quality, Regulatory Compliance,
Environmental Health & Safety,
and Occupational Health
Bernardo Tavares
Chief Data &
Technology Officer
Information Technology and Data
Science
Paul Ruh
Chief Financial Officer
Thibaut Mongon
Chief Executive Officer
Investor Relations, Controller,
Treasury, Tax, Global Audit &
Assurance, Business Finance, and
TSA Management
Matt Orlando
General Counsel
Legal, Corporate Secretary,
Intellectual Property, Brand Protection,
Compliance, Privacy, and Corporate
Security
9

-- 9 of 27 --



-- 10 of 27 --



-- 11 of 27 --

CEO Remarks
Sales Performance and Earnings Review
Capital Allocation and Guidance
Q&A
12
Agenda
1
2
3
4
Joaquin Duato
Chief Executive Officer
Joseph J. Wolk
Executive Vice President
Chief Financial Officer
Jessica Moore
Vice President
Investor Relations

-- 12 of 27 --

Regional Sales Results Q2 2022 Q2 2021
% CHANGE
Reported Operational1
U.S. $12.2 $11.9 2.3% 2.3%
Europe 6.1 5.7 7.3 20.7
Western Hemisphere
(ex U.S.) 1.5 1.4 12.4 14.9
Asia-Pacific, Africa 4.2 4.4 (3.6) 4.7
International 11.8 11.4 3.8 13.9
Worldwide (WW) $24.0 $23.3 3.0% 8.0%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
2nd Quarter 2022 Sales
Dollars in Billions
13

-- 13 of 27 --

4.4%; 10.9%1
Q2 2022 Q2 2021
$2.59 $2.48
2nd Quarter 2022 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational %1
14
Sales
Adjusted Earnings2 Adjusted EPS2
3.0%; 8.0%1
$24.0 $23.3
GAAP Earnings
(23.3)%
$4.8
$6.3
4.3%
Q2 2022 Q2 2021
GAAP EPS
(23.4)%
$1.80
$2.35
Q2 2022	Q2 2022 Q2 2021 Q2 2021	Q2 2022 Q2 2021
$6.9 $6.6
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website

-- 14 of 27 --

OTC
$1,482
Skin Health/Beauty
$1,126
Oral Care
$394
Baby Care
$375
Women's Health
$230
Wound Care/Other
$197
$3,805
(1.3)%, 2.3%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Consumer Health Highlights – 2nd Quarter 2022
Solid adjusted operational growth2 driven by OUS OTC
15
Key Drivers of Operational Performance1,3
OTC3
• Growth driven by strong OUS Cough/Cold/Flu season and strong performance of
IMODIUM due to digestive health category recovery in EMEA as well as antifungal
performance in ASPAC coupled with price actions partially offset by supply constraints
and softer allergy season in the U.S.
Skin
Health/
Beauty
• Decline driven by supply constraints, competitive pressures, DR. CI LABO Sedona
divestiture in ASPAC and regional COVID-19 related mobility restrictions partially offset
by pricing actions coupled with lapping prior year negative one-time events and strong
new product introductions in ASPAC
Oral Care • Decline driven by regional COVID-19 related mobility restrictions, divestiture in EMEA
and lapping prior year COVID-19 related demand increases
Baby Care • Slight growth driven by OUS performance due to price actions in LATAM and higher
demand in ASPAC mostly offset by supply constraints primarily in the U.S.
Women’s
Health
• Growth driven by ASPAC performance due to strength in STAYFREE Secure XL in
India, price actions and strong consumer demand and increased distribution in EMEA
Wound
Care/Other
• Decline driven by lapping prior year higher demand and professional tape divestiture
partially offset by supply recovery in Canada
Adjusted Operational Sales2,3: WW 2.9%, U.S. (3.4)%, Int’l 8.1%
Reported3: WW (1.3)%, U.S. (3.6)%, Int’l 0.6%
Operational1,3: WW 2.3%, U.S. (3.6)%, Int’l 7.3%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding
3.8%, 7.5%
0.2%, 7.2%
(8.4)%, (7.4)%
(3.1)%, 0.5%
(7.3)%, (4.0)%
(3.7)%, (0.3)%
3

-- 15 of 27 --

Key Drivers of Operational Performance1,3
Immunology
• Growth driven by continued strong uptake of STELARA in Crohn’s Disease and
Ulcerative Colitis, as well as the net benefit of favorable discounts partially offset by a
prior period adjustment
• Strength in TREMFYA due to market share gains in both Psoriasis and Psoriatic
Arthritis partially offset by an unfavorable prior period adjustment
• REMICADE decline due to biosimilar competition
Infectious
Diseases3
• Growth driven by the contribution of the COVID-19 Vaccine
• Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and
PREZISTA OUS LOE
Neuroscience3
• Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA driven by new patient starts
and persistency, as well as the launch of INVEGA HAFYERA
Oncology
• DARZALEX increase driven by share gains in all regions, continued strong market
growth and solid uptake of the subcutaneous formulation
• Continued strong global launch uptake of ERLEADA
• IMBRUVICA maintained its market leadership position but declined due to competitive
pressures. U.S. decline partially offset by growth in all regions OUS
Cardiovascular/
Metabolism/
Other
(CVM/Other)3
• XARELTO driven by volume growth and share gains from commercial access changes
• INVOKANA/INVOKAMET decline due to continued share erosion
Pulmonary
Hypertension
(PH)
• Growth driven by strong demand and share gains from UPTRAVI
• Partially offset by COVID-19 related market constraints across the portfolio and
unfavorable patient mix in OPSUMIT
• Continued declines in Other Pulmonary Hypertension
Adjusted Operational Sales2,3: WW 12.4%, U.S. 4.4%, Int’l 22.2%
Immunology
$4,411
Infectious Diseases
$1,316
Neuroscience
$1,734
Oncology
$4,042
CVM/Other
$972
PH
$843	$13,317
6.7%, 12.3%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Pharmaceutical Highlights – 2nd Quarter 2022
16
Reported3: WW 6.7%, U.S. 4.2%, Int’l 9.8%
Operational1,3: WW 12.3%, U.S. 4.2%, Int’l 22.1%
(4.8)%, (3.1)%
(3.1)%, 0.9%
14.3%, 21.9%
(3.9)%, 0.5%
29.3%, 42.0%
4.3%, 8.1%
Continued above-market performance primarily driven by Oncology and Immunology
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding
3
3
3

-- 16 of 27 --

Orthopaedics
$2,157
Surgery
$2,450
Vision
$1,241
Interventional
Solutions
$1,049
$6,898
(1.1)%, 3.4%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
MedTech Highlights – 2nd Quarter 2022
Operational growth1 reflects continued commercial execution & innovation partially offset by impacts related to COVID-19
17
Reported: WW (1.1)%, U.S. 1.6%, Int’l (3.6)%
Operational1: WW 3.4%, U.S. 1.6%, Int’l 5.1%
Key Drivers of Operational Performance1
Interventional
Solutions
• Market growth in U.S., EMEA, & LATAM coupled with success of new products and commercial strategies
continuing to enhance competitiveness partially offset by regional COVID-19 related mobility restrictions
Orthopaedics
• Hips: Growth reflects strength of the portfolio (ACTIS Stem and enabling technologies KINCISE & VELYS Hip
Navigation) and momentum in the U.S. Ambulatory Surgery Center channel partially offset by regional COVID-19
related mobility restrictions
• Trauma: Growth driven by uptake of new products (Cannulated Compression Headless Screws, Advanced Nailing
Systems and FIBULINK) partially offset by regional COVID-19 related mobility restrictions
• Knees: Growth driven primarily by market recovery and new products, including pull through related to the VELYS
Robotic assisted solution partially offset by regional COVID-19 related mobility restrictions and timing of OUS
tenders (~ -200bps)
• Spine, Sports & Other: Decline driven primarily by continued complex Spine procedural softness and regional
COVID-19 related mobility restrictions partially offset by new products in Sports, Spine & VELYS Digital Solutions
• Spine: WW: ~ -8%, U.S.: ~ -9%, OUS ~ -7%
Surgery
• Advanced:
• Endocutters: ~ +4% Driven by commercial activities to expand access and new products (ECHELON Staple
Line Reinforcement) aided by a reclass from General Surgery (~ +200bps) partially offset by regional
COVID-19 related mobility restrictions and competitive pressures in the U.S.
• Biosurgery: ~ +2% Reflects market expansion efforts and success of new products (VISTASEAL &
SURGICEL POWDER) partially offset by strong market demand in the prior year for infection prevention
products and regional COVID-19 related mobility restrictions
• Energy: ~ +4% Driven by new product penetration (ENSEAL X1 Curved & HARMONIC 1100) coupled with
competitive supply challenges and stocking OUS (~ +250bps) partially offset by regional COVID-19 related
mobility restrictions
• General: Reflects strength of the Suture portfolio and technology penetration (Barbed Sutures & Topical Skin
Adhesives) mostly offset by regional COVID-19 related mobility restrictions and softness in Breast Augmentation
market
Vision
• Contact Lenses/Other: Growth driven primarily by market, commercial execution, new products partially offset by
lapping prior year stocking in the U.S. (~ -200bps) and regional COVID-19 related mobility restrictions
• Surgical: Growth primarily driven by Cataract market recovery and market share gains driven by recent TECNIS
Eyhance and Synergy IOL launches, and timing of stocking in ASPAC (~ +250bps) partially offset by high prior
year comp in Refractive
Adjusted Operational Sales2: WW 3.4%, U.S. 1.4%, Int’l 5.3%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding; The MedTech segment was previously referred to as the Medical Devices segment
0.3%, 5.3%
4.9%, 10.9%
(3.1)%, 0.5%
(2.8)%, 1.8%

-- 17 of 27 --

2022 2021 %
Increase
(Decrease)	Amount % to Sales Amount % to Sales
Sales to customers $24,020 100.0 $23,312 100.0 3.0
Cost of products sold 7,919 33.0 7,587 32.5 4.4
Gross Profit 16,101 67.0 15,725 67.5 2.4
Selling, marketing and administrative expenses 6,226 25.9 6,073 26.1 2.5
Research and development expense 3,703 15.4 3,394 14.6 9.1
In-process research and development - - - -
Interest (income) expense, net (26) (0.1) 28 0.1
Other (income) expense, net 273 1.1 (488) (2.1)
Restructuring 85 0.4 56 0.2
Earnings before provision for taxes on income 5,840 24.3 6,662 28.6 (12.3)
Provision for taxes on income 1,026 4.3 384 1.7 167.2
Net Earnings $4,814 20.0 $6,278 26.9 (23.3)
-
Net earnings per share (Diluted) $1.80 $2.35 (23.4)
Average shares outstanding (Diluted) 2,667.9 2,671.6
Effective tax rate 17.6% 5.8%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income $8,171 34.0 $7,776 33.4 5.1
Net earnings $6,912 28.8 $6,625 28.4 4.3
Net earnings per share (Diluted) $2.59 $2.48 4.4
Effective tax rate 15.4% 14.8%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 18
2nd Quarter 2022
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 18 of 27 --

2022 2021
Adjusted Income Before Tax by Segment1
2nd Quarter 2022
19
Pharmaceutical
MedTech
Consumer Health
Expenses Not Allocated to Segments
2Q 2022 2Q 2021
Pharmaceutical3 42.0% 39.4%
MedTech 26.5% 28.6%
Consumer Health3 25.9% 28.6%
Total 34.0% 33.4%
% to Sales
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 Estimated as of 7/19/2022
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
($0.2) ($0.2)
$7.8B
$4.9
$2.0
$1.1
$8.2B
$5.6
$1.8
$1.0
2

-- 19 of 27 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 20 of 27 --

Notable Announcements in 2nd Quarter 20221
Pharmaceutical
• Regulatory Decisions:
– European Commission Grants Conditional Approval of CARVYKTI (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, for the Treatment of
Patients with Relapsed and Refractory Multiple Myeloma
– Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple
Myeloma
– Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously
Untreated Chronic Lymphocytic Leukemia (CLL)
• Other:
– New Data Show TREMFYA (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated
Mechanism from Risankizumab
– Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at
ASCO and EHA
MedTech
– ETHICON Launches Next Generation ECHELON 3000 Stapler Designed for Exceptional Access and Control
Enterprise
– Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company
– Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public
Commitments
21	1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com

-- 21 of 27 --

Capital Allocation Strategy
Capital Allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
HIGHER
PRIORITY
LOWER
PRIORITY
Investment in M&A
Dollars in Billions Q2 2022
Cash and Marketable
Securities $33
Debt ($33)
Net Debt $0
Free Cash Flow1,2 ~$8
Q2 2022:
$3.7B invested in R&D;
$7.2B year-to-date
$3.0B in dividends paid
to shareholders;
$5.8B year-to-date
Note: values may have been rounded
1 Non-GAAP measure; cash flow from operations less CAPEX
2 Estimated as of July 19, 2022. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings 22

-- 22 of 27 --

1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: July 2022 = $1.05; Euro Spot Rate: July 2022 = $1.00 6 Excludes COVID-19 Vaccine
Note: Percentages may be rounded. 23
July April Comments
Adjusted Operational Sales1,2,6 6.5% - 7.5% 6.5% - 7.5% Maintain
Operational Sales2,6 $97.3B - $98.3B
6.5% - 7.5%
$97.3B - $98.3B
6.5% - 7.5% Maintain
Estimated Reported Sales3,6 $93.3B - $94.3B
2.1% - 3.1%
$94.8B - $95.8B
3.8% - 4.8% Incremental FX ($1.5B)
Adjusted Pre-Tax
Operating Margin4,5 Approximately Flat ~50 bps improvement Decreasing due to prolonged
inflationary pressures
Net Other Income4 $1.4 - $1.5 billion $1.2 - $1.4 billion Increasing & tightening
of the range
Net Interest Expense /
(Income) $0 $0 - $100 million Decreasing based on
year-to-date trends
Effective Tax Rate4 15.0% - 15.5% 15.5% - 16.5% Lowering & tightening
of the range
Adjusted EPS (Operational)2,4 $10.65 - $10.75
8.7% - 9.7%
$10.60 - $10.80
8.2% - 10.2%
Tightening of range
Maintain midpoint
Adjusted EPS (Reported)3,4 $10.00 - $10.10
2.1% - 3.1%
$10.15 - $10.35
3.6% - 5.6% Incremental FX ($0.20)
2022 P&L Guidance
Company maintains midpoints of Adjusted Operational Sales and Adjusted Operational EPS

-- 23 of 27 --

Source: The New York Times; FactSet
As of July 13, 2022, 8:42AM EST 24
Euro Falls to Equal the U.S. Dollar for the First
Time in 20 Years

-- 24 of 27 --

2022 Sales Considerations
Consumer Health
• Anticipate stronger 2H vs. 1H due to
continued market recovery, competitive
momentum, and growth from recently
launched products
• Expect Q4 to slightly outperform Q3
• Continue to monitor COVID-19 and
related dynamics
MedTech
• Anticipate external supply constraints to
lessen throughout remainder of the year
• Benefit of strategic price increases in
the back half of the year
Pharmaceutical
1 Non-GAAP measure; excludes acquisitions and divestitures 4 Excludes COVID-19 Vaccine
2 Non-GAAP measure; excludes the impact of translational currency Note: Percentages may be rounded
3 Euro Average Rate: July 2022 = $1.05; Euro Spot Rate: July 2022 = $1.00
Phasing Considerations by Segment
• Continue to anticipate another year of
above-market adjusted operational
sales growth
• Expect modest sales acceleration
through the end of the year
July April
Adjusted Operational Sales1,2,4 6.5% - 7.5% 6.5% - 7.5%
Operational Sales2,4 $97.3B - $98.3B
6.5% - 7.5%
$97.3B - $98.3B
6.5% - 7.5%
Estimated Reported Sales3,4 $93.3B - $94.3B
2.1% - 3.1%
$94.8B - $95.8B
3.8% - 4.8%
25

-- 25 of 27 --

Q&A
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Chief Executive Officer
Joaquin Duato

-- 26 of 27 --



-- 27 of 27 --